Reversing insulin resistance with AI-driven lifestyle modification. Vitadio develops prescription digital therapeutics (DTx) that combine evidence-based medicine and proprietary AI to support personalised behaviour change for people with type 2 diabetes and prediabetes.

We focus on treating the cause, not the symptoms, by delivering daily personalised guidance, real-time diet feedback and proactive human support. Vitadio is clinically proven in multiple peer-reviewed studies, is a Class I medical device under MDR, and is ISO 27001 and GDPR compliant. Headquartered in Prague and Berlin, the product is available in Czech, Italian and German and is covered by statutory health insurers in Germany.

We are hiring and continue to expand across Europe to improve cardiometabolic health at scale.